The FTC is asking a US Court of Appeals to revisit a lawsuit from Mylan against Allergan, which claims that Allergan changed the formula of antibiotic Doryx to stymie its competition. Allergan sold the US rights to the drug earlier this year to Mayne Pharmaceuticals.
Even though a trial judge dismissed Mylan’s claims, saying that the company failed to prove any anticompetitive action on the part of Allergan, the FTC doesn’t see things quite the same way.
The practice of tweaking brand-name drugs, or “product-hopping,” can harm consumers who save billions a year through generic meds, the commission said in a statement. Product hopping could also undercut laws that allow pharmacists to automatically swap out brand-name drugs with lower-cost copycats, it added, further jeopardizing fair play.
“A company is unlikely to face potential antitrust liability if it does not take targeted steps to damage the market for the original formulation and instead allows the marketplace itself to choose between that formulation and the modified version,” the FTC said in its amicus brief.
Full content: Regulatory Affairs Professionals Society
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI